Navigation Links
Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma
Date:5/27/2008

Results Fail to Show Statistically Significant Improvement in Primary

Endpoint, Time to Progression, Compared to Control

SAN DIEGO, May 27 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL) today announced results from the Company's Phase 3 registration trial of Specifid(TM) following Rituxan(R) in patients with follicular B-cell non-Hodgkin's lymphoma (NHL).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO )

Analysis of time to progression (TTP), the primary endpoint in the trial, failed to show a statistically significant improvement in the treatment arm, Specifid plus Leukine(R) (sargramostim, GM-CSF) following Rituxan, compared to the control arm, placebo plus Leukine following Rituxan. Analysis of all subgroups also did not show any significant differences in primary or secondary endpoints when adjusted for prognostic factors.

The safety profile was comparable between the two arms and consistent with what has been observed in previous Specifid trials. Most adverse events reported in the trial were of low grade.

"We are clearly very disappointed with the data from this trial, particularly on behalf of the patients and their families," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "Based on these results, we are discontinuing development of Specifid and are currently evaluating steps to conserve cash and recognize value on our assets. We wish to thank all of our employees and the patients, clinical investigators and trial coordinators for their support and dedication."

About the Phase 3 Registration Trial

Favrille initiated its Phase 3 randomized, placebo-controlled, double-blind registration trial of Specifid for follicular B-cell NHL in July 2004. The Company completed enrollment in January 2006 with 349 patients randomized into the trial. The trial was open to both treatment-naive and previously treated patients, ultimately enrolling a much larger treatment-naive population (78%). Patients were randomized at a one-to-one ratio to receive either Specifid or placebo following a standard course of Rituxan. The trial was conducted at 67 centers in the U.S.

Conference Call and Webcast

Favrille's management team will host a conference call today at 8:30 a.m. Eastern Time to discuss the information contained in this press release. A live audio webcast will be available on the Investor Relations section of the Company's web site at http://www.favrille.com . Alternatively, callers may participate in the conference call by dialing (866) 831-6267 or (617) 213-8857, passcode 99549869. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 20389415.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to continue its operations, conserve cash or recognize value on our assets and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Favrille Reports First Quarter 2008 Financial Results
2. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
3. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
4. Favrille Announces $21.1 Million Registered Direct Offering
5. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
6. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
7. Favrille to Present at BIO InvestorForum
8. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
9. Favrille CEO to Present at Bear Stearns Healthcare Conference
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Diego, CA (PRWEB) , ... April 20, 2017 , ... ... management of clinical trials worldwide, announced today that they were named one of the ... , which covers the latest developments in the pharmaceutical industry. , “We take pride ...
(Date:4/20/2017)... N.J. and PETACH TIKVAH, Israel ... BCLI), a leading developer of adult stem cell technologies for ... Executive Officer, will present at the Alliance for Regenerative Medicine,s ... Day on Thursday, April 27, 2017 at 09:40 EDT in ... Ralph Kern , MD, MHSc, Chief Medical Officer & ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments ... which is part of the Protein and Cell Analysis Education Webinar Series , ... this technology fits in current and future applications. , Many flow cytometers have ...
(Date:4/19/2017)... ... , ... Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical Trial ... its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, Inc. announced ... of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. ...
Breaking Biology Technology:
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology ... object recognition technologies, today announced the release of ... (SDK), which provides improved facial recognition using up ... on a single computer. The new version uses ... improve accuracy, and it utilizes a Graphing Processing ...
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare announces ... spirometer and Wellness Management System (WMS), a remote, real-time ... in 2010, PMD Healthcare is a Medical Device, Digital ... mission dedicated to creating innovative solutions that empower people ... that intent focus, PMD developed the first ever personal ...
Breaking Biology News(10 mins):